Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis

Sotatercept for the Treatment of Pulmonary Arterial Hypertension

(2021) Marc Humbert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

(2021) Marius M Hoeper et al.   Lancet Respiratory Medicine

Mortality trends in pulmonary arterial hypertension in canada: a temporal analysis of survival per ESC/ERS Guideline Era

(2021) Jason G.E. Zelt et al.   EUROPEAN RESPIRATORY JOURNAL

Temporal trends in pulmonary arterial hypertension: Results from the COMPERA registry

(2021) Marius M. Hoeper et al.   EUROPEAN RESPIRATORY JOURNAL

COMPERA 2.0: A refined 4-strata risk assessment model for pulmonary arterial hypertension

(2021) Marius M. Hoeper et al.   EUROPEAN RESPIRATORY JOURNAL

External validation of a refined 4-strata risk assessment score from the French pulmonary hypertension Registry

(2021) Athénaïs Boucly et al.   EUROPEAN RESPIRATORY JOURNAL

Development and Validation of an Abridged Version of the REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for use in Patients with Pulmonary Arterial Hypertension

(2020) Raymond L. Benza et al.   CHEST

Idiopathic pulmonary arterial hypertension phenotypes determined by cluster analysis from the COMPERA registry

(2020) Marius M. Hoeper et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Predicting Survival in Patients with Pulmonary Arterial Hypertension

(2019) Raymond L. Benza et al.   CHEST

PULMONARY ARTERIAL HYPERTENSION PATIENTS WITH AND WITHOUT CARDIOVASCULAR RISK FACTORS: RESULTS FROM THE AMBITION TRIAL

(2019) Vallerie V. McLaughlin et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension: A Double-Blind, Placebo-Controlled Study

(2019) R. James White et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

The Low-Risk Profile in Pulmonary Arterial Hypertension. Time for a Paradigm Shift to Goal-oriented Clinical Trial Endpoints?

(2018) Jason Weatherald et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

REVEAL risk scores applied to riociguat-treated patients in PATENT-2: Impact of changes in risk score on survival

(2018) Raymond L. Benza et al.   JOURNAL OF HEART AND LUNG TRANSPLANTATION

Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality

(2018) Vallerie V. McLaughlin et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Clinical trial design and new therapies for pulmonary arterial hypertension

(2018) Olivier Sitbon et al.   EUROPEAN RESPIRATORY JOURNAL

A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension

(2017) David Kylhammar et al.   EUROPEAN HEART JOURNAL

Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model

(2017) Marius M. Hoeper et al.   EUROPEAN RESPIRATORY JOURNAL

Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension

(2017) Athénaïs Boucly et al.   EUROPEAN RESPIRATORY JOURNAL

Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension

(2015) Vallerie McLaughlin et al.   EUROPEAN RESPIRATORY JOURNAL

Selexipag for the Treatment of Pulmonary Arterial Hypertension

(2015) Olivier Sitbon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

(2015) Nazzareno Galiè et al.   NEW ENGLAND JOURNAL OF MEDICINE

Baseline and Follow-up 6-Min Walk Distance and Brain Natriuretic Peptide Predict 2-Year Mortality in Pulmonary Arterial Hypertension

(2013) Jason S. Fritz et al.   CHEST

Functional Class Improvement and 3-Year Survival Outcomes in Patients With Pulmonary Arterial Hypertension in the REVEAL Registry

(2013) Robyn J. Barst et al.   CHEST

Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension

(2013) Marius M. Hoeper et al.   CIRCULATION

Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

(2013) Tomás Pulido et al.   NEW ENGLAND JOURNAL OF MEDICINE

Riociguat for the Treatment of Pulmonary Arterial Hypertension

(2013) Hossein-Ardeschir Ghofrani et al.   NEW ENGLAND JOURNAL OF MEDICINE

The Minimal Important Difference in the 6-Minute Walk Test for Patients with Pulmonary Arterial Hypertension

(2012) Stephen C. Mathai et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Do Changes of 6-Minute Walk Distance Predict Clinical Events in Patients With Pulmonary Arterial Hypertension?

(2012) Gianluigi Savarese et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Biomarkers and surrogate endpoints in clinical trials

(2012) Thomas R. Fleming et al.   STATISTICS IN MEDICINE

Usefulness of Serial N-Terminal Pro–B-Type Natriuretic Peptide Measurements for Determining Prognosis in Patients With Pulmonary Arterial Hypertension

(2011) Gert-Jan Mauritz et al.   AMERICAN JOURNAL OF CARDIOLOGY

Race and Sex Differences in Response to Endothelin Receptor Antagonists for Pulmonary Arterial Hypertension

(2011) Nicole B. Gabler et al.   CHEST

Landmark Analysis at the 25-Year Landmark Point

(2011) Urania Dafni  

Tadalafil Therapy for Pulmonary Arterial Hypertension

(2009) Nazzareno Galiè et al.   CIRCULATION

Ambrisentan for the Treatment of Pulmonary Arterial Hypertension

(2008) Nazzareno Galiè et al.   CIRCULATION